- Home
- RBOT vs JSPR Comparison
RBOT vs JSPR Comparison
Compare RBOT & JSPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RBOT | JSPR |
|---|---|---|
| Founded | 2014 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.1M | 48.1M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | RBOT | JSPR |
|---|---|---|
| Price | $2.24 | $1.92 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 2 | 11 |
| Target Price | $7.00 | ★ $21.44 |
| AVG Volume (30 Days) | 164.2K | ★ 3.9M |
| Earning Date | 11-12-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.16 | $1.39 |
| 52 Week High | $18.97 | $22.99 |
Technical Indicators
Market Signals| Indicator | RBOT | JSPR |
|---|---|---|
| Relative Strength Index (RSI) | 31.33 | 54.73 |
| Support Level | $2.16 | $1.61 |
| Resistance Level | $2.58 | $1.96 |
| Average True Range (ATR) | 0.29 | 0.16 |
| MACD | 0.03 | 0.03 |
| Stochastic Oscillator | 5.41 | 92.11 |
Price Performance
Historical ComparisonAbout RBOT Vicarious Surgical Inc.
Vicarious Surgical Inc designs a surgical robot that enables surgeons to perform minimally invasive surgery with 3D visualization and accurate control. Its Vicarious Surgical Robotic System is designed with a focus on abdominal access and visualization through a single port. The company has following segment: Research and development, Sales and marketing, General and administrative.
About JSPR Jasper Therapeutics Inc.
Jasper Therapeutics Inc is a clinical-stage biotechnology company dedicated to enabling cures through hematopoietic stem cell therapy. It is focused on the development and commercialization of safer and more effective conditioning agents and stem cell engineering to allow for expanded use of stem cell transplantation and ex vivo gene therapy.